Lifespan.io reports back from Aging Research and Drug Discovery Meeting (ARDD 2023)
Lifespan.io (LEAF) - 26-Sep-2023Key points from Arkadi Mazin's summary of 5 days of talks by geroscientists and biotech leaders
Kelsey Moody
CEO of Ichor Therapeutics focussed on drug discovery that impacts the pathways of aging
Dr. Moody is a process-oriented drug developer and executive who has specialized in the study of aging and aging mechanisms for over a decade. Since 2013, Dr. Moody has successfully built Ichor Therapeutics from a living room start-up into a premier, vertically integrated research organization focused on drug discovery and development for pathways of aging.
Dr. Moody is a process-oriented drug developer and executive who has specialized in the study of aging and aging mechanisms for over a decade. Since 2013, Dr. Moody has raised over $30 million in venture capital and successfully built Ichor Life Sciences (formerly Ichor Therapeutics) from a living room start-up into a premier, vertically integrated research organization.
Visit website: https://ichorlifesciences.com/our-team/
See also: 
Ichor Therapeutics
- Company that develops clinical products in the field of regenerative medicine
Details last updated 24-Oct-2019
Kelsey Moody is also referenced in the following:
ARDD 2023 - 10th Aging Research & Drug Discovery Meeting
28-Aug-2023 to 01-Sep-2023
Event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen
Healthy Masters International Conference
05-Nov-2022 to 06-Nov-2022
Healthy Masters conference about living longer and healthier life
Interview with Ichor CEO Kelsey Moody
Kelsey Moody, CEO of Ichor Life Sciences, shares updates on the company’s latest research
Longevity Summit Dublin 2023
17-Aug-2023 to 20-Aug-2023
Club discount available - click here
Event gathering Global Longevity and Rejuvenation community in Dublin with many longevity movement superstars as speakers
Kelsey Moody News
Lento Bio raised $680,000 aiming to restore near vision in presbyopia patients
Lento Bio - 06-Sep-2022Ichor Life Sciences leads the investment to advance anti-glycation therapies
Lento bio to launch anti-glycation drugs targeting anti-aging and presbyopia
Ichor Therapeutics - 06-Jun-2022Lento Bio research into molecular aging damage by accelerating clinical assets
Lysoclear is making progress towards a cure for macular degeneration
Lifespan.io (LEAF) - 25-Sep-2019Has cleared protein build up in vivo - has funding to develop clinical candidates
LEAF interviews Ichor Therapeutics CEO
Lifespan.io (LEAF) - 12-Feb-2019$16m raided, FoxBio partnership with Juvenescence, lots going on
LEAF report from the Longevity Leaders Conference
Lifespan.io (LEAF) - 06-Feb-2019Encouraging signs from big companies - more interviews to follow
FoxBio is developing small molecule drugs to target ageing diseases
Business Wire - 12-Jul-2018Antoxerene partners with Juvenescence to discover drugs that clear senescent cells
